Merus N.V. — Investor Relations & Filings

Merus N.V. is a clinical-stage oncology company focused on the discovery and development of innovative, full-length multispecific antibody therapeutics for cancer. The company utilizes its proprietary Biclonics® and Triclonics® technology platforms to engineer bispecific and trispecific antibodies designed to engage multiple targets simultaneously and harness the immune system's power. Its clinical pipeline includes multiple candidates targeting various cancers. Key programs include petosemtamab, being investigated for head and neck squamous cell carcinoma, and zenocutuzumab, which received accelerated approval from the U.S. FDA for the treatment of patients with NRG1 fusion-positive non-small cell lung cancer and pancreatic cancer.